Scarica l'app Stockscreener
61.03
3.00%
-1.89
Dopo l'orario di chiusura:
60.68
-0.35
-0.57%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARWR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$62.92
Aprire:
$60.41
Volume 24 ore:
1.45M
Relative Volume:
0.52
Capitalizzazione di mercato:
$8.55B
Reddito:
$1.09B
Utile/perdita netta:
$233.57M
Rapporto P/E:
39.68
EPS:
1.5382
Flusso di cassa netto:
$327.01M
1 W Prestazione:
+0.43%
1M Prestazione:
-5.13%
6M Prestazione:
+76.39%
1 anno Prestazione:
+380.93%
Intervallo 1D:
$60.41
$63.32
Intervallo di 1 settimana:
$57.01
$64.86
Portata 52W:
$9.57
$76.76
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Nome
Arrowhead Pharmaceuticals Inc
Settore
Industria
Telefono
626-696-4702
Indirizzo
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
61.03 | 8.55B | 1.09B | 233.57M | 327.01M | 1.5382 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-05 | Iniziato | Goldman | Neutral |
| 2023-12-04 | Iniziato | BofA Securities | Buy |
| 2023-09-19 | Iniziato | Citigroup | Neutral |
| 2023-07-21 | Iniziato | TD Cowen | Outperform |
| 2023-05-12 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | Iniziato | SMBC Nikko | Outperform |
| 2023-04-12 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-11 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | Ripresa | Goldman | Buy |
| 2021-08-06 | Reiterato | Chardan Capital Markets | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-11-19 | Iniziato | Citigroup | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-05-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-04-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | Iniziato | Goldman | Neutral |
| 2020-01-21 | Iniziato | SVB Leerink | Underperform |
| 2019-12-13 | Iniziato | Oppenheimer | Perform |
| 2019-11-29 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-27 | Reiterato | B. Riley FBR | Buy |
| 2019-11-25 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | Reiterato | Chardan Capital Markets | Buy |
| 2019-10-03 | Iniziato | Robert W. Baird | Outperform |
| 2018-09-07 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | Reiterato | Chardan Capital Markets | Buy |
| 2018-08-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-07-02 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie
Arrowhead Pharmaceuticals Inc (HDP1.HM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Arrowhead Pharmaceuticals, Inc. (A2RR34.SA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Tema Etfs LLC Reduces Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals Leads with 415.53% Return in Stock Performance - Markets Mojo
ARWR Stock Price, Quote & Chart | ARROWHEAD PHARMACEUTICALS IN (NASDAQ:ARWR) - ChartMill
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Arrowhead (ARWR) FQ1 2026 revenue hits $264M as REDEMPLO approval marks commercial shift - MSN
Arrowhead Pharmaceuticals, Inc. (ARWR) Jumps 7.3% to $61.87 - AlphaStreet
Q4 2025 Arrowhead Pharmaceuticals Inc Earnings Call Transcript - gurufocus.com
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and Expo - MarketScreener
Arrowhead Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Arrowhead Plozasiran Data Supports Triglyceride Reduction And Valuation Upside Potential - finance.yahoo.com
Arrowhead Pharmaceuticals (ARWR) price target increased by 17.24% to 59.24 - MSN
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo - Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Sp - pharmiweb.com
Trading Systems Reacting to (ARWR) Volatility - Stock Traders Daily
Arrowhead Pharmaceuticals Inc (LTS:0HI3) Bonds - GuruFocus
BofA Securities Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Cuts Target Price to $81 - moomoo.com
Stock List: Research Stocks from Around the World - GuruFocus
Vanguard amendment shows 0% holding in Arrowhead (ARWR) - Stock Titan
Arrowhead Pharma stock rating reiterated at Buy by TD Cowen - Investing.com South Africa
Analysts Conflicted on These Healthcare Names: Cibus (CBUS), Arrowhead Pharmaceuticals (ARWR) and Tarsus Pharmaceuticals (TARS) - The Globe and Mail
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap DownWhat's Next? - MarketBeat
BofA cuts Arrowhead Pharma stock price target on obesity prospects By Investing.com - Investing.com India
BofA cuts Arrowhead Pharma stock price target on obesity prospects - Investing.com
Sarepta Pushes Past Gene Therapy Debacle as RNA Therapies Show Early Promise - BioSpace
Arrowhead Pharmaceuticals: Transition Phase With Moderate Upside Ahead (NASDAQ:ARWR) - seekingalpha.com
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Strong One Year Shareholder Return - Sahm
Leerink reiterates Arrowhead Pharma stock rating on partner data By Investing.com - Investing.com Canada
Arrowhead Pharmaceuticals Surges as Clinical Trial Doses First Patients - StocksToTrade
Arrowhead Pharma (ARWR) Rating Reiterated as 'Buy' by HC Wainwri - gurufocus.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Receives "Buy" Rating from HC Wainwright - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Up 8.6%Here's What Happened - MarketBeat
Johnson & Johnson Exits 3 Biotechs but Keeps Stakes in These Rumored Acquisition Targets - Barron's
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Nordea Investment Management AB - MarketBeat
Assenagon Asset Management S.A. Purchases 304,264 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
JPMorgan Chase & Co. Grows Stake in Arrowhead Pharmaceuticals, Inc. $ARWR - marketbeat.com
Exit Recap: Whats the beta of Arrowhead Pharmaceuticals Inc stockWeekly Gains Summary & High Yield Equity Trading Tips - baoquankhu1.vn
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Hudson Bay Capital Management LP - MarketBeat
Arrowhead Shareholders Reject Say-on-Pay at 2026 Meeting - The Globe and Mail
B of A Securities Maintains Arrowhead Pharmaceuticals (ARWR) Buy Recommendation - MSN
Arrowhead Pharmaceuticals (NASDAQ: ARWR) holders back board but reject Say-on-Pay - stocktitan.net
Arrowhead Advances Zodasiran Into Phase 3 HoFH Study, Signaling Long-Term Growth Potential - TipRanks
A Look At Arrowhead Pharmaceuticals (ARWR) Valuation As Recent Momentum Cools After A Strong Run - Yahoo Finance
Arrowhead’s bid to become a large-cap biotech - BioCentury
Arrowhead Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
A Look At Arrowhead Pharmaceuticals (ARWR) Valuation As Fisher Builds Stake And SHASTA Readouts Approach - Sahm
Arrowhead Pharmaceuticals Inc. (ARWR): Billionaire Ken Fisher Bets Big on Pharma - Insider Monkey
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
Arrowhead Pharmaceuticals (ARWR) Is Down 5.4%What's Changed - simplywall.st
Arrowhead Pharmaceuticals earns $100M milestone from Sarepta Therapeutics - MSN
Arrowhead Pharmaceuticals Inc Azioni (ARWR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):